Trial Profile
Tyrosine Kinase Inhibitors of BCR/ABL: Pharmacokinetic and Pharmacogenetic Study in Patients Affected by Chronic Myeloid Leukemia. Evaluation of Efficacy and Tolerability
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 12 Oct 2023
Price :
$35
*
At a glance
- Drugs Imatinib (Primary) ; Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions; Pharmacogenomic; Pharmacokinetics; Therapeutic Use
- Acronyms TIKIet
- 05 Oct 2023 Planned End Date changed from 30 Nov 2022 to 31 Dec 2024.
- 05 Oct 2023 Planned primary completion date changed from 31 May 2022 to 31 Dec 2024.
- 04 Jan 2022 Planned End Date changed from 30 Nov 2021 to 30 Nov 2022.